

Dependent Neurotrophic factor III (ADNF III) and a specific eight amino acid peptide denoted as NAP (NAPVSIQ) derived from the cloned ADNF III. NAP has been discovered to have potent neuroprotective properties in vitro and in vivo. NAP has been shown to significantly reduce the number of apoptotic cells and to protect neurons against numerous toxins and cellular stresses including in vitro excitotoxicity, oxidative stress, and glucose deprivation. NAP also exhibits neuroprotective activity in a variety of animal models including a learning deficient apolipoprotein E knockout mice (a model related to Alzheimer's disease), mouse paradigms of traumatic head injury (associated with an inflammatory response) and fetal alcohol syndrome (oxidative stress), and a rat model of cholinitoxicity.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: May 28, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.
[FR Doc. 02-15147 Filed 6-14-02; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Cytotoxic Treatment of Cancer Cells That Overexpress Matrix Metalloproteinases, Plasminogen Activators and/or Plasminogen Activator Receptors

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR Part 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Patent Application, 60/155,961 (refiled): "Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinase or plasminogen activator receptors" (DHHS Ref. E-293-99/0); PCT Patent Application, PCT/US00/26192 [WO01/21656] (refiled): "Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinase or plasminogen activator receptors" (DHHS Ref. E-293-99/1); U.S. Patent Application, S/N 10/088,952: "Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinase or plasminogen activator receptors" (DHHS Ref. E-293-99/2); U.S. Patent 5,591,631, S/N 08/021,601, which issued on January 7, 1997 (DHHS Ref. E-064-93/0), entitled, "Anthrax toxin fusion proteins, nucleic acid encoding same"; U.S. Patent 5,677,274, S/N 08/082,849, which issued on October 14, 1997 (DHHS Ref. E-064-93/1), entitled, "Anthrax toxin fusion proteins and related methods"; and any related foreign filed national stage applications claiming priority to such cases to OncoTac Pharmaceuticals which is located in Medicon Valley, Denmark. The patent rights in these inventions have been assigned to the United States of America.

The prospective exclusive license territory will be worldwide and the field of use may be limited to human therapeutics for the treatment of cancer by a mechanism involving cancer-associated enzymes and/or receptors.

DATES: Only written comments and/or license applications that are received by the National Institutes of Health on or before August 16, 2002, will be considered.

ADDRESSES: Requests for copies of the patent, inquiries, comments and other materials relating to the contemplated exclusive license should be directed to: Richard U. Rodriguez, M.B.A., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD. 20852-3804. Telephone: (301) 496-7056, X287; Facsimile: (301) 402-0220; and E-mail: rodrigur@od.nih.gov.

SUPPLEMENTARY INFORMATION: The primary technology relates to an immunotoxin treatment system that is targeted to cancer cells via an anthrax-based pathway. Native anthrax toxin is a three-component toxin consisting of protective antigen (PrAg), lethal factor (LF), and edema factor (EF). PrAg binds to the recently identified cell surface anthrax receptor and the subsequent steps in toxin action is dependent on cleavage of PrAg at the sequence, ¹⁶⁴RKKR1⁶⁷, by a cell-surface, furin-like protease. The carboxyl-terminal 63-kDa fragment (PrAg63) remains bound to receptor, forms a heptamer, and binds and internalizes LF and EF. LF kills animals and lyses mouse macrophages due to proteolytic cleavage of MAP kinase kinases. EF damages cells due to its intracellular adenylate cyclase activity. A potent PrAg dependent cytotoxin, FP59, created by fusing LF amino acids 1-254 to the ADP-ribosylation domain of *Pseudomonas* exotoxin A can kill any cell having receptors for PrAg and the ability to activate PrAg by cleavage at amino acids 164-167.

Activation of the native PrAg is dependent on a cell surface located furin-like proteolytic activity. In the current technology, the furin-site has been manipulated to generate mutant PrAg proteins that are specific for matrix metalloproteinases (MMPs) or the urokinase plasminogen activator (uPA). A combination of the mutated toxins PrAg and FP59 has been shown to be an effective cytotoxic agent that is strictly dependent on cell surface localized MMP and/or uPA-activity.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective exclusive license may be granted unless within sixty (60) days from the date of this published notice, the NIH receives written evidence and argument that establish that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7.

Applications for a license in the field of use filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: June 7, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 02-15148 Filed 6-14-02; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Withdrawal of Group II Portion of Guidance for Applicants SM 02-009, Targeted Capacity Expansion: Meeting the Mental Health Services Needs of Older Adults

AGENCY: Center for Mental Health Services (CMHS), Substance Abuse and Mental Health Services Administration (SAMHSA), DHHS.

ACTION: Notice of withdrawal of Group II portion of Guidance for Applicants SM 02-009, Targeted Capacity Expansion: Meeting the Mental Health Services Needs of Older Adults.

SUMMARY: This notice is to inform the public that the SAMHSA/CMHS is withdrawing the Group II portion of the Guidance for Applicants (GFA) No. SM 02-009, Targeted Capacity Expansion: Meeting the Mental Health Services Needs of Older Adults (Short Title: Older Adult Mental Health Services). The application date for this GFA is June 19, 2002. The Group II award is for a National Technical Assistance Center for the Mental Health Needs of Older Adults. The Group I component of the program is unaffected by this announcement.

SAMHSA/CMHS will substantially revise and reissue the Group II component of the GFA for funding in Fiscal Year 2002. SAMHSA/CMHS believes that it is programatically advantageous to remove the PRISME element, which was work begun under a previous award, from the general technical assistance element. This will enable the National Technical Assistance Center to focus on the core technical assistance and information dissemination functions of the Center while allowing the Government Project Officer to maintain a direct connection with the PRISME project. Check the **Federal Register** and the SAMHSA web site for notice of the new announcement at <http://www.samhsa.gov/>.

Targeted Capacity Expansion: Meeting the Mental Health Services Needs of Older Adults grants support the adoption and implementation of evidence-based practices related to the delivery and organization of services for

older adults with serious serious mental illness or who are at risk for serious mental illness. Awards for the Group I component of this program are limited to a maximum of \$400,000 in total costs. The award for the Group II component is limited to a maximum of \$1,400,000.

Program Contact: For questions concerning program issues, contact: Betsy McDonel Herr, Ph.D., Community Support Program, Room 11C-22, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2197, Fax 301-443-0541, E-mail: bmcdonel@samhsa.gov.

Dated: June 12, 2002.

Richard Kopanda,

Executive Officer, SAMHSA.

[FR Doc. 02-15333 Filed 6-13-02; 2:59 pm]

BILLING CODE 4162-20-P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4739-17]

Notice of Proposed Information Collection: Comment Request; Eligibility of a Nonprofit Corporation

AGENCY: Office of the Assistant Secretary for Housing-Federal Housing Commissioner, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: Comments due Date: August 16, 2002.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Wayne Eddins, Reports Management Officer, Department of Housing and Urban Development, 451 7th Street, SW., L'Enfant Plaza Building, Room 8003, Washington, DC 20410.

FOR FURTHER INFORMATION CONTACT: Michael McCullough, Director, Office of Multifamily Development, Department of Housing and Urban Development, 451 7th Street, SW., Washington, DC 20410, telephone (202) 708-1142 (this is not a toll-free number) for copies of the proposed forms and other available information.

SUPPLEMENTARY INFORMATION: The Department is submitting the proposed information collection to OMB for review, as required by the Paperwork

Reduction act of 1995 (44 U.S.C. Chapter 35, as amended).

This Notice is soliciting comments from members of the public and affected agencies concerning the proposed collection of information to: (1) Evaluate whether the proposed collection is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond; including the use of appropriate automated collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

This Notice also lists the following information:

Title of Proposal: Eligibility of a Nonprofit Corporation.

OMB Control Number, if applicable: 2502-0057.

Description of the need for the information and proposed use: This information collection is needed to enable HUD to determine the qualifications of a nonprofit to successfully sponsor a multifamily housing project. A nonprofit is defined as an entity organized for reasons other than financial gain. The information collected will also be used to determine the nonprofit's motive for sponsoring the project and identify any contractual relationship that exists between HUD and the nonprofit.

Agency Form numbers, if applicable: HUD-3433, HUD-3434, and HUD-3435.

Estimation of the total number of hours need to prepare the information collection including the number of respondents, frequency of response, and hours of response: The estimated total number of annual hours needed to prepare the information collection is 90; the number of respondents is 270 generating 270 annual responses; the frequency of response is on occasion or once during the application periods; and the estimated time needed per response varies from 15 minutes to 45 minutes.

Status of the proposed information collection: Extension of currently approved collection.

Authority: The Paperwork Reduction Act of 1995, 44 U.S.C. Chapter 35, as amended.